Cargando…
Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy
PURPOSE: The objective of the present study was to develop a liposomal drug delivery system based on combretastatin A4 (CA4) prodrugs modified with varying alkyl chains and investigate the in vitro drug conversion from prodrug and in vivo antitumor effect. METHODS: The prodrug of CA4 was synthesized...
Autores principales: | Gu, Yongwei, Ma, Juanjuan, Fu, Zhiqin, Xu, Youfa, Gao, Baoan, Yao, Jianzhong, Xu, Wei, Chu, Kedan, Chen, Jianming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844228/ https://www.ncbi.nlm.nih.gov/pubmed/31806973 http://dx.doi.org/10.2147/IJN.S210938 |
Ejemplares similares
-
Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects
por: Jiang, Hong, et al.
Publicado: (2019) -
In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
por: Grosios, K, et al.
Publicado: (1999) -
Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4
por: Lian, Bo, et al.
Publicado: (2021) -
Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study
por: Wu, Chan, et al.
Publicado: (2018) -
Magnetic resonance imaging and spectroscopy of combretastatin A(4) prodrug-induced disruption of tumour perfusion and energetic status
Publicado: (1998)